IDH2 and central nervous system cancer: I-X glioma—GBM like; multiple molecular subgroups, distinct from IDH1/ATRX/TP53 (I-A glioma) and IDH/CIC/FUBP1 (I-CF glioma) tumors—prognosis approximately 1 year.